|
|
||||||||
RESEARCH REPORT |
1 Departments of Microbiology-Box 1, 2 Medicine, and 3 Oral Diagnostics, University of Alabama at Birmingham, 845 19th Street South, Birmingham, AL 35294-2170;
* corresponding author, jannovak{at}uab.edu
| ABSTRACT |
|---|
|
|
|---|
KEY WORDS: IgG N-glycans periodontal disease galactose deficiency.
| INTRODUCTION |
|---|
|
|
|---|
In many respects, periodontal disease shares some common features with other chronic inflammatory diseases, particularly with rheumatoid arthritis, including: production of IgM and IgA rheumatoid factor (Hirsch et al., 1989); infiltration of inflamed tissue with mainly IgG-secreting plasma cells (Ogawa et al., 1989); production of auto-antibodies to tissue components (collagen II in rheumatoid arthritis; collagens I and III in periodontal disease; Hirsch et al., 1988); similar cytokine profiles (Fujihashi et al., 1993; Pistoia, 1997); and increased levels of IL-6 (Fujihashi et al., 1993; Pistoia, 1997).
Extensive structural studies of IgG molecules produced at the site of chronic inflammation and detectable in the circulation revealed profound alterations in the glycan moieties. Specifically, deficiencies of some monosaccharides, especially galactose on IgG, have been described in human chronic inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease, tuberculosis, and infection with HIV (Mullinax and Mullinax, 1975; Parekh et al., 1985 , 1988; Tomana et al., 1988; Bodman et al., 1992; Tsuchiya et al., 1993; Rademacher et al., 1994; Tomana, 1996; Moore et al., 2005). IgG contains one complex-type oligosaccharide (Fig. 1A
) per each heavy chain linked to the conserved glycosylation site on asparagine 297 within constant region domain 2, which presumably has a role in maintaining the three-dimensional structure of the Fc portion of IgG. In IgG with galactose-deficient glycans, the terminally exposed sugar molecule is N-acetylglucosamine. Analysis of experimental data has indicated that galactose-deficient IgG is pathogenic (Rademacher et al., 1994): Galactose-deficient IgG binds to the mannan-binding lectin and thus activates the complement cascade by the lectin pathway (Malhotra et al., 1995). Furthermore, glycans on IgG molecules affect binding and internalization by Fc receptors expressed on phagocytic cells (Krapp et al., 2003) and, thus, influence opsonization of antigens by phagocytosis.
|
| MATERIALS & METHODS |
|---|
|
|
|---|
ELISA
We used binding of Psathyrella velutina lectin (PVL) to examine galactose-deficiency of N-linked glycans on IgG molecules. PVL detects galactose-deficient N-linked glycans through their binding to terminal N-acetylglucosamine (Tsuchiya et al., 1993). IgG (or serum diluted 1:1000) was reduced, alkylated, and captured on protein-G-coated plates, and the presence of terminal N-acetylglucosamine was probed with biotin-labeled PVL. Simultaneously, IgG levels were also measured by ELISA; the relative N-acetylglucosamine content of IgG-containing samples was expressed as PVL/IgG ratio.
Gas-liquid Chromatography Analysis of IgG Monosaccharide Composition
The monosaccharides from purified IgG proteins were determined as trifluoroacetates of methyl-glycosides by gas chromatography, as described previously (Tomana et al., 1984). The analyses were performed with a Hewlett-Packard model 5890 series II gas chromatograph equipped with a 25-m fused silica (0.22-mm inner diameter) OV-1701 WCOT column and electron capture detector; GC ChemStation software (Agilent Technologies, Palo Alto, CA, USA) was used for acquisition of chromatographic data and peak integration. The galactose content in IgG was determined relative to that of mannose, since the latter was shown to be constant in patients with various autoimmune diseases and in normal healthy controls (Tomana et al., 1988). About 50 µg of each IgG was used for the analyses.
Immunofluorescence
Gingiva- and periodontium-containing tissues removed from periodontal disease patients for therapeutic purposes were examined by immunofluorescence microscopy. The tissue was stained with fluorescein isothiocyanate- (FITC) or tetramethylrhodamine isothiocyanate- (TRITC) labeled F(ab')2 fragments of antibodies recognizing human IgG, and with biotin-labeled PVL followed by avidin conjugated with 7-amino-4-methyl-coumarin-3-acetate (AMCA) for determination of the presence of IgG-producing cells and the production of galactose-deficient IgG. Tissue fixation and processing were conducted as previously described (Kilian et al., 1989). Control tissues included gingivae from patients who underwent crown-lengthening with no evidence of periodontal disease. The staining performed on such tissues showed the absence or scarcity of IgG-producing cells in healthy gingivae. In addition, all tissues were stained by hematoxylin-eosin so that the cell types present could be determined. Seven gingivae samples from periodontal disease patients and six gingivae samples from normal controls were used.
Statistical Analysis
Correlation coefficients (r) were calculated by means of the Microsoft Excel statistical package. Comparisons between group means were performed by Students t test. P values equal to or less than 0.05 were considered statistically significant.
| RESULTS |
|---|
|
|
|---|
PVL reactivity of IgG in sera from 14 periodontal disease patients and 10 healthy controls had mean OD values ± SD of 0.63 ± 0.32 and 0.25 ± 0.22, respectively (P = 0.0046; Fig. 2A
). This result indicated that sera from periodontal disease patients contained more galactose-deficient IgG compared with that from normal healthy controls.
|
Gingivae from periodontal disease patients with well-developed and uncontrolled disease contained infiltration of plasma cells, producing mostly IgG. To examine whether these IgG-producing cells secrete galactose-deficient IgG, we have used double-immunofluorescence with anti-IgG antibody and PVL. From the results of immunohistochemical staining, we concluded that a proportion of IgG-producing cells contained galactose-deficient IgG in the cytoplasm (Fig. 3
).
|
| DISCUSSION |
|---|
|
|
|---|
A growing body of evidence indicates that glycan moieties on glycoproteins, including immunoglobulins, play an essential role in many biological processes and functions (Varki, 1993). For example, glycans on immunoglobulin molecules participate in binding to Fc receptors expressed on phagocytic cells (Monteiro et al., 1990; Leader et al., 1991), opsonization of antigens for phagocytosis, and activation of complement (Tao et al., 1993). These essential functions of immunoglobulin-associated glycans have been demonstrated by studies of immunoglobulin molecules modified by various glycosidases or chemical cleavages, replacement of asparagine with other amino acid residues by site-directed mutagenesis, or inhibitors of glycosylation (e.g., tunicamycin) in immunoglobulin-producing cells (Leader et al., 1991). Polymorphism of IgG glycosylation is associated with variable interactions with Fc
RIII receptor and activation of the complement cascade through the lectin pathway (Malhotra et al., 1995). The role of glycans in complement activation indicated that, in such molecules, N-acetylglucosamine, which becomes the terminal glycan in galactose-deficient IgG, binds mannan-binding lectin. In turn, this may result in local complement activation by complexes composed of tissue auto-antigens or microbial antigens (see below) and corresponding antibodies, all with inflammatory consequences. Importantly, IgA and IgG4 that normally do not activate complement become complement-binding isotypes when glycan moieties are altered (Parekh et al., 1985; Garred et al., 1989; Russell et al., 1997; Tao et al., 1993). Galactose-deficient IgG4 may, in tissues, activate complement, with all the resultant inflammatory consequences. Thus, the anti-inflammatory properties of IgA and IgG4, manifested by their ability to interfere with IgG1-, IgG2-, and IgG3-mediated complement activation, are lost due to their altered glycans (Russell et al., 1989, 1997).
In autoimmune diseases, such as rheumatoid arthritis, tissue components and cartilage collagen Type II, in particular, are the autoantigens recognized by galactose-deficient IgG molecules (Rademacher et al., 1994). We have demonstrated, in our earlier studies, that in periodontal disease, collagens Type I and III are recognized by locally produced IgG antibodies (Hirsch et al., 1988). Therefore, in addition to antigens derived from bacteria associated with periodontal disease, tissue autoantigens may also be targets of IgG antibodies that, in turn, activate, in the form of immune complexes, complement cascade with all its inflammatory sequelae and subsequent tissue damage.
Glycosylation of immunoglobulins is mediated by a large family of enzymesglycosyltransferasesspecific for individual carbohydrates (Schachter and Roseman, 1980). These enzymes catalyze the transfer of intracellularly activated monosaccharides (e.g., UDP-galactose) to suitable acceptors. The decreased levels of glycosyltransferases or their functional deficiency results in reduced or absent glycosylation of the acceptorin this case, IgG molecules. Differentiation of B-cells is regulated by several cytokines, particularly IL-6 (Fujihashi et al., 1993; Pistoia, 1997), whose increased levels may result in decreased glycosylation. In view of the fact that high levels of IL-6 are produced by mononuclear cells isolated from the gingivae of patients with periodontal disease (Fujihashi et al., 1993), it is possible that, in addition to the stimulation of local B-cell differentiation into immunoglobulin-secreting plasma cells abundant in the inflamed gingiva (Kilian et al., 1989; McGhee et al., 1989; Ogawa et al., 1989), decreased galactosylation of IgG further enhances the inflammatory response.
Overall, these results suggest a possibility that, in periodontal disease, the terminal differentiation of B-cells is affected, resulting in the production of pro-inflammatory galactose-deficient IgG.
| ACKNOWLEDGMENTS |
|---|
Received December 9, 2004; Last revision April 15, 2005; Accepted June 29, 2005
| REFERENCES |
|---|
|
|
|---|
Fujihashi K, Kono Y, Beagley KW, Yamamoto M, McGhee JR, Mestecky J, et al. (1993). Cytokines and periodontal disease: immunopathological role of interleukins for B cell responses in chronic inflamed gingival tissues. J Periodontol 64:400406.[ISI][Medline]
Garred P, Michaelsen TE, Aase A (1989). The IgG subclass pattern of complement activation depends on epitope density and antibody and complement concentration. Scand J Immunol 30:379382.[ISI][Medline]
Grbic JT, Singer RE, Jans HH, Celenti RS, Lamster IB (1995). Immunoglobulin isotypes in gingival crevicular fluid: possible protective role of IgA. J Periodontol 66:5561.[ISI][Medline]
Hirsch HZ, Tarkowski A, Miller EJ, Gay S, Koopman WJ, Mestecky J (1988). Autoimmunity to collagen in adult periodontal disease. J Oral Pathol 17:456459.[ISI][Medline]
Hirsch HZ, Tarkowski A, Koopman WJ, Mestecky J (1989). Local production of IgA- and IgM-rheumatoid factors in adult periodontal disease. J Clin Immunol 9:273278.[ISI][Medline]
Kilian M, Ellegaard B, Mestecky J (1989). Distribution of immunoglobulin isotypes including IgA subclasses in adult, juvenile, and rapidly progressive periodontitis. J Clin Periodontol 16:179184.[ISI][Medline]
Kinane DF, Lappin DF, Koulouri O, Buckley A (1999). Humoral immune responses in periodontal disease may have mucosal and systemic immune features. Clin Exp Immunol 115:534541.[ISI][Medline]
Krapp S, Mimura Y, Jefferis R, Huber R, Sondermann P (2003). Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J Mol Biol 325:979989.[ISI][Medline]
Leader KA, Kumpel BM, Hadley AG, Bradley BA (1991). Functional interactions of aglycosylated monoclonal anti-D with Fc gamma RI+ and Fc gamma RIII+ cells. Immunology 72:481485.[ISI][Medline]
Malhotra R, Wormald MR, Rudd PM, Fischer PB, Dwek RA, Sim RB (1995). Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nature Med 1:237243; erratum 1:559.[ISI][Medline]
McGhee ML, Ogawa T, Pitts AM, Moldoveanu Z, Mestecky J, McGhee JR, et al. (1989). Cellular analysis of functional mononuclear cells from chronically inflamed gingival tissue. Reg Immunol 2:103110.[Medline]
Monteiro RC, Kubagawa H, Cooper MD (1990). Cellular distribution, regulation, and biochemical nature of an Fc alpha receptor in humans. J Exp Med 171:597613.
Moore JS, Wu X, Kulhavy R, Tomana M, Novak J, Moldoveanu Z, et al. (2005). Increased levels of galactose-deficient IgG in sera of HIV-1-infected individuals. AIDS 19:381389.[ISI][Medline]
Mullinax F, Mullinax GL (1975). Abnormality of IgG structure in rheumatoid arthritis and systemic lupus erythematosus. Arthritis Rheum 18:417418.
Ogawa T, McGhee ML, Moldoveanu Z, Hamada S, Mestecky J, McGhee JR, et al. (1989). Bacteroides-specific IgG and IgA subclass antibody-secreting cells isolated from chronically inflamed gingival tissues. Clin Exp Immunol 76:103110.[ISI][Medline]
Parekh RB, Dwek RA, Sutton BJ, Fernandes DL, Leung A, Stanworth D, et al. (1985). Association of rheumatoid arthritis and primary osteoarthritis with changes in glycosylation pattern of total serum IgG. Nature 316:452457.[Medline]
Parekh RB, Roitt IM, Isenberg DA, Dwek RA, Ansell BM, Rademacher TW (1988). Galactosylation of IgG associated oligosaccharides: reduction in patients with adult and juvenile onset rheumatoid arthritis and relation to disease activity. Lancet 2(8592):966969.
Pistoia V (1997). Production of cytokines by human B cells in health and disease. Immunol Today 18:343350.[ISI][Medline]
Rademacher TW, Williams P, Dwek RA (1994). Agalactosyl glycoforms of IgG autoantibodies are pathogenic. Proc Natl Acad Sci USA 91:61236127.
Russell MW, Reinholdt J, Kilian M (1989). Anti-inflammatory activity of human IgA antibodies and their Fab
fragments: inhibition of IgG-mediated complement activation. Eur J Immunol 19:22432249.[ISI][Medline]
Russell MW, Sibley DA, Nikolova EB, Tomana M, Mestecky J (1997). IgA antibody as a non-inflammatory regulator of immunity. Biochem Soc Trans 25:466470.[ISI][Medline]
Schachter H, Roseman S (1980). Mammalian glycosyltransferases. In: The biochemistry of glycoproteins and proteoglycans. Lennarz WJ, editor. New York: Plenum Press, pp. 85160.
Socransky SS, Haffajee AD, Cugini MA, Smith C, Kent RL Jr. (1998). Microbial complexes in subgingival plaque. J Clin Periodontol 25:134144.[ISI][Medline]
Tao MH, Smith RI, Morrison SL (1993). Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. J Exp Med 178:661667.
Tomana M (1996). Glycoproteins in inflammatory bowel disease. In: Glycoproteins in disease. Montreuil J, Vliegenhart JFG, Schachter H, editors. Amsterdam: Elsevier, pp. 291298.
Tomana M, Prchal JT, Garner LC, Skalka HW, Barker SA (1984). Gas chromatographic analysis of lens monosaccharides. J Lab Clin Med 103:137142.[ISI][Medline]
Tomana M, Schrohenloher RE, Koopman WJ, Alarcon G, Paul WA (1988). Abnormal glycosylation of serum IgG from patients with chronic inflammatory diseases. Arthritis Rheum 31:333338.[ISI][Medline]
Tsuchiya N, Endo T, Matsuta K, Yoshinoya S, Takeuchi F, Nagano Y, et al. (1993). Detection of glycosylation abnormality in rheumatoid IgG using N-acetylglucosamine-specific Psathyrella velutina lectin. J Immunol 151:11371146.[Abstract]
Varki A (1993). Biological roles of oligosaccharides: all of the theories are correct. Glycobiology 3:97130.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| IADR Journals | Advances in Dental Research ® |
| Journal of Dental Research ® | Critical Reviews (1990-2004) |